You are here
Home > Blog > JUST IN: WHO Approves China’s Sinopharm COVID Vaccine For Use

JUST IN: WHO Approves China’s Sinopharm COVID Vaccine For Use

Spread the love

China’s Sinopharm COVID-19 vaccine has been approved for emergency use by the World Health Organisation (WHO).

This development was contained in a statement on Friday in which WHO said the decision was part of efforts to improve access to vaccines to curb the spread of the coronavirus.

Sinopharm is the sixth vaccine after Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Janssen and Moderna vaccines, listed for emergency use.

The emergency use listing (EUL), according to the global health body, will also provide more options for countries interested in accessing vaccines via the United Nations-led COVAX facility — African countries are procuring vaccines via the COVAX facility.Though Nigeria has begun using the AstraZeneca vaccine, the Presidential Taskforce on COVID-19 has expressed interest in China’s Sinopharm vaccine.An excerpt of the statement from the website of the WHO reads:

“WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).

“WHO’s Emergency Use Listing (EUL) is a prerequisite for COVAX Facility vaccine supply. It also allows countries to expedite their own regulatory approval to import and administer COVID-19 vaccines.

“In the case of the Sinopharm vaccine, the WHO assessment included on-site inspections of the production facility. The Sinopharm product is an inactivated vaccine called SARS-CoV-2 Vaccine (Vero Cell). Its easy storage requirements make it highly suitable for low-resource settings. It is the also first vaccine that will carry a vaccine vial monitor, a small sticker on the vaccine vials that change color as the vaccine is exposed to heat, letting health workers know whether the vaccine can be safely used.

“WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) has also completed its review of the vaccine. On the basis of all available evidence, WHO recommends the vaccine for adults 18 years and older, in a two-dose schedule with a spacing of three to four weeks. Vaccine efficacy for symptomatic and hospitalised disease was estimated to be 79%, all age groups combined.

“Few older adults (over 60 years) were enrolled in clinical trials, so efficacy could not be estimated in this age group.  Nevertheless, WHO is not recommending an upper age limit for the vaccine because preliminary data and supportive immunogenicity data suggest the vaccine is likely to have a protective effect in older persons.

“There is no theoretical reason to believe that the vaccine has a different safety profile in older and younger populations. WHO therefore recommends that countries using the vaccine in older age groups conduct safety and effectiveness monitoring to make the recommendation more robust.”

Lady Decency
Decency Global News is one of the world's finest blog you can see anywhere around the world. We deal on fresh facts with indept analysis & investigative reporting across the globe. We advertise & market goods & services for corporate bodies and individuals as well as event management & Public Relations consultation…. We appreciate constructive criticism to serve you better. Welcome & enjoy the news... Contact: ella4decency@gmail.com Tell: +234 803 744 6365 +33757936595
Top